CD3δ/CD3ε and CD3γ/CD3ε have the ability to develop the TCR-CD3 complexes through the α/β chain of TCR as heterodimers. Generally, CD3-targeted therapeutic antibodies recognize the CD3ε in ...

11,12 (8) Synthetic TCR antigen receptor/HLA-independent TCR (STAR/HIT) constructs retain the full complex of CD3 signaling but also have high antigen sensitivity via the fusion of an antibody binding ...

that consists of a soluble TCR targeting gp100 expressed on cancer cells fused to a protein that binds CD3 receptors on lymphocytes – as a treatment for unresectable or metastatic uveal melanoma.

Dr. Saef Izzy, Associate Professor of Neurology at Harvard Medical School, commented, “Treatment with nasal anti-CD3 not only dampened microglial activation but also led to marked improvements in ...